High-sensitivity troponin testing is enabling earlier detection of myocardial injury and supporting faster diagnostic pathways for patients with suspected heart attacks.
A University of Warwick study finds AI cancer detection models may rely on statistical correlations rather than true biomarker signals, raising concerns about reliability in clinical pathology applications.
The FDA has granted Breakthrough Device Designation to MeMed BV Flex, an AI-powered capillary blood test designed to distinguish bacterial from viral infections in 15 minutes using host-response biomarkers.
The AI companion analyzes up to five years of personal lab data within the company's patient portal to explain test results and identify health trends.
20/20 BioLabs argues a tiered screening approach—starting with protein-based tests before moving to circulating tumor DNA testing or imaging—could improve early-stage detection and lower costs.
